BioCentury | Feb 2, 2018
Company News

Amicus to build U.S. biologics facility

...GAA (rhGAA), and AT2221, a pharmacological chaperone. Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Business: Endocrine/Metabolic Chris Lieu ATB200/AT2221 Amicus...
BioCentury | Jan 12, 2018
Company News

Spark unveils gene therapy program for Pompe's

...Monday it will provide an update on a regulatory pathway for the candidate this half. ATB200/AT2221...
...GAA (rhGAA), and AT2221, a pharmacological chaperone. Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Business: Endocrine/Metabolic Allison Johnson AT982 ATB200/AT2221 AVD-RD-03 Lumizyme SPK-GAA Amicus...
BioCentury | Jan 9, 2018
Company News

Spark to develop gene therapy for Pompe's

...Monday it will provide an update on a regulatory pathway for the candidate this half. ATB200/AT2221...
BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / Metabolic

...recombinant human GAA (rhGAA), in Phase I/II testing to treat Pompe’s disease. Amicus also has ATB200/AT2221...
BioCentury | Nov 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

...recombinant human GAA (rhGAA), in Phase I/II testing to treat Pompe’s disease. Amicus also has ATB200/AT2221...
BioCentury | Oct 6, 2017
Clinical News

Amicus reports function outcomes data from Phase I/II of Pompe's disease candidate

...Inc. (NASDAQ:FOLD) reported functional outcomes data from the Phase I/II ATB200-02 Study showing that IV ATB200/AT2221...
...non-ambulatory ERT-switch patients; and ERT-naïve patients. Among 9 evaluable ambulatory ERT-switch patients at 6 months, ATB200/AT2221...
...ATB200/AT2221 led to no serious adverse events in the trial (see BioCentury, Jan. 20 ). ATB200/AT2221...
BioCentury | Oct 4, 2017
Clinical News

Amicus eyeing 'fastest path' for Pompe's therapy

...Wednesday after reporting additional efficacy data from a Phase I/II trial showing that combo therapy ATB200/AT2221...
...patients; non-ambulatory ERT-switch patients; and ERT-naïve patients. Among nine evaluable ERT-switch patients at six months, ATB200/AT2221...
...expects to report additional data from patients who have received the combo for a year. ATB200/AT2221...
BioCentury | Jan 20, 2017
Clinical News

ATB200/AT2221: Preliminary Ph I/II ATB200-02 Study data

...received enzyme replacement therapy (ERT) in the open-label, international Phase I/II ATB200-02 Study showed that ATB200/AT2221...
...high-dose AT2221 at weeks 14, 16 and 18. Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Product: ATB200/AT2221...
...Endpoint: Safety and pharmacokinetics Status: Preliminary Phase I/II data Milestone: Additional Phase I/II data (2017) Alicia Parker ATB200/AT2221 Amicus...
Items per page:
1 - 8 of 8